The Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania.
Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota.
JAMA Ophthalmol. 2018 May 1;136(5):543-547. doi: 10.1001/jamaophthalmol.2018.0554.
Patients with myotonic dystrophy (MD) have an increased risk of malignancy including uveal melanoma. This case series further explores the association between these 2 diseases.
To describe a cohort of patients with uveal melanoma associated with MD, including a case of iris melanoma, and MD-associated uveal melanoma in relatives.
DESIGN, SETTING, AND PARTICIPANTS: Retrospective case series at 3 tertiary referral centers (Wills Eye Hospital, Philadelphia, Pennsylvania; Mayo Clinic, Rochester, Minnesota; and Moorfields Eye Hospital, London, England), between January 1, 2000, and August 31, 2017. The study included 6 patients with MD and uveal melanoma.
Melanoma response to treatment and development of metastatic disease.
There were 6 patients, 4 men and 2 women, with MD and uveal melanoma. The mean patient age at melanoma diagnosis was 47 years (median, 43 years; range, 30-67 years), and the tumor involved the choroid in 5 patients (83%) and iris in 1 patient (17%). The diagnosis of MD was known since young adulthood in 2 patients (33%) and was discovered in adulthood in 4 patients (67%). The main clinical features of MD included muscle weakness (n = 5; 83%), myotonia (n = 4; 67%), polychromatic cataract (n = 4; 67%), complications with general anesthesia (n = 4; 67%), myalgia (n = 3; 50%), cardiac arrhythmia (n = 2; 33%), and frontal baldness (n = 2; 33%). Genetic testing revealed MD type 1 (4 of 4 tested patients), and 2 patients demonstrated positive family history of MD with classic clinical features and preferred no testing. Melanoma treatment included plaque radiotherapy (n = 4; 67%), photodynamic therapy (n = 1; 17%), and declined treatment (n = 1; 17%). At follow-up of 6, 6, 41, 42, and 87 months (5 patients), findings included melanoma regression (4 of 5 tumors), melanoma recurrence (1 of 5 tumors), and no metastatic disease (5 of 5 patients).
Six adult patients with MD demonstrated uveal melanoma involving the choroid or iris, emphasizing the association between these 2 diseases. Further research seems warranted to explore the pathogenesis of uveal melanoma in MD. These findings support the consideration of ophthalmic examination for uveal melanoma in patients with MD.
患有肌强直性营养不良(MD)的患者恶性肿瘤风险增加,包括葡萄膜黑色素瘤。本病例系列进一步探讨了这两种疾病之间的关联。
描述一组与 MD 相关的葡萄膜黑色素瘤患者,包括虹膜黑色素瘤和 MD 相关的葡萄膜黑色素瘤的家族史。
设计、地点和参与者:在 3 家三级转诊中心(宾夕法尼亚州费城的威尔斯眼医院、明尼苏达州罗切斯特的梅奥诊所和英国伦敦的摩尔菲尔德眼医院)进行的回顾性病例系列研究,时间为 2000 年 1 月 1 日至 2017 年 8 月 31 日。该研究纳入了 6 例 MD 和葡萄膜黑色素瘤患者。
黑色素瘤对治疗的反应和转移性疾病的发展。
有 6 名男性和 2 名女性患者患有 MD 和葡萄膜黑色素瘤。黑色素瘤诊断时患者的平均年龄为 47 岁(中位数为 43 岁;范围为 30-67 岁),5 例患者(83%)肿瘤累及脉络膜,1 例患者(17%)累及虹膜。2 例患者(33%)在成年后即确诊为 MD,4 例患者(67%)在成年后才发现 MD。MD 的主要临床特征包括肌肉无力(n=5;83%)、肌强直(n=4;67%)、多色性白内障(n=4;67%)、全身麻醉并发症(n=4;67%)、肌痛(n=3;50%)、心律失常(n=2;33%)和额部脱发(n=2;33%)。基因检测显示 MD 1 型(4 例患者均为阳性),2 例患者有阳性家族史,有典型的临床特征,选择不进行基因检测。黑色素瘤治疗包括斑块放射治疗(n=4;67%)、光动力疗法(n=1;17%)和拒绝治疗(n=1;17%)。随访 6、6、41、42 和 87 个月(5 例患者)时,结果包括黑色素瘤消退(5 例肿瘤中有 4 例)、黑色素瘤复发(5 例肿瘤中有 1 例)和无转移性疾病(5 例患者均无)。
6 例成年 MD 患者出现累及脉络膜或虹膜的葡萄膜黑色素瘤,强调了这两种疾病之间的关联。似乎需要进一步研究以探讨 MD 中葡萄膜黑色素瘤的发病机制。这些发现支持在 MD 患者中考虑进行眼部检查以筛查葡萄膜黑色素瘤。